Sign In
Buy PFE
$25.36
-0.200 (-0.783%)
At Close: Jun 03, 2026
Pfizer to acquire Metsera after winning bidding contest against Novo Nordisk
11:53am, Monday, 10'th Nov 2025
Metsera (NASDAQ:MTSR) announced that it has entered into an amended merger agreement with Pfizer Inc (NYSE:PFE, ETR:PFE), under which Pfizer will acquire the biotech company for up to $86.25 per shar
Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B
10:46am, Monday, 10'th Nov 2025
Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.
Pfizer to buy Metsera in deal worth up to $10 billion
10:30am, Monday, 10'th Nov 2025
Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Metsera accepted
Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs
10:21am, Monday, 10'th Nov 2025
Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company's up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer's strategy for clinical de
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
10:00am, Monday, 10'th Nov 2025
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
5 Things to Know Before the Stock Market Opens
09:10am, Monday, 10'th Nov 2025
Stock futures are surging this morning after U.S. lawmakers passed a key procedural hurdle as part of an agreement that could bring an end to the shutdown that has lasted nearly six weeks; President D
End of Shutdown Hopes Send Stock Futures Surging
09:09am, Monday, 10'th Nov 2025
Stock futures are surging as a possible end to the longest-ever government shutdown comes into play
Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.
08:05am, Monday, 10'th Nov 2025
Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, with more money and help from the Trump administration.
Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Winner.
07:32am, Monday, 10'th Nov 2025
The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.
Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
07:00am, Monday, 10'th Nov 2025
Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board's research, drug development and commercialization expertise Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board's resea
Dividend Income: Lanny's September 2025 Summary
05:27am, Monday, 10'th Nov 2025
In September, we (my wife and I) received a dividend income total of $5,342.09. Our dividend income went up almost $1,000 from last year. We had more stocks increase last month, but the increases this
U.S. Senate Makes Progress on Shutdown Deal, Novo Nordisk Loses Out to Pfizer
03:45am, Monday, 10'th Nov 2025
The U.S. Senate progressed a deal towards ending the longest U.S. Government shutdown in history. Eight democrats joined all but one republican in voting to move forward with a funding bill that will
Wall Street Brunch: Here Come The 13Fs
01:31pm, Sunday, 09'th Nov 2025
13F filings this week will reveal hedge fund and institutional moves, offering insight into smart money positioning amid recent market highs. Earnings season is winding down, with 90% of S&P 500 compa
Pfizer wins $10 billion bidding war for obesity drug developer
04:14pm, Saturday, 08'th Nov 2025
Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo's bid that it had previously called superior.
Pfizer clinches $10 billion Metsera deal, outbidding Novo Nordisk
09:54am, Saturday, 08'th Nov 2025
Pfizer acquires Metsera for $10 billion, cementing their new obesity treatment strategy. The purchase concludes a weeklong bidding frenzy between the New York-based pharmaceutical company and Danish h
